| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |